[A20-34] Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2020
Project no.:
A20-34
Commission:
Commission awarded on 30.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic Merkel cell carcinoma
Added benefit not proven due to lack of suitable study data: single-arm approval study does not provide a comparison with the appropriate comparator therapy.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-95 | Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G17-09 | Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V | Commission completed |
| A21-23 | Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |